		· · · · · · · · · · · · · · · · · · ·	1					
PTO-144	9 REPR	ODUCED		ATTORNEY DOCKET NO. 3033.1000-008	APPLICAT		っトハ	/EI
	INFO	RMATION DISCLOSURE CI IN AN APPLICATION	NOITATION	APPLICANT Darrell H. Carney	<u> </u>	HE.	Y 2 4	2002
	/15 AUS	April 2, 2002	essarv)	FILING DATE January 16, 2002	GROUP 1653	TECHC	FNTER	160012
-/-	Chose	o the kil		PATENT DOCUMENTS	<u> </u>	TEOTTO		
EXAM- INER INI-	MAY	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING I APPROF	
TIAL	AA	5,352,664	10/04/94	Carney et al.	514	13 R	ECE	IVE
190	AB	5,500,412	03/19/96	Carney et al.	514		UN 2 (2002
age .		3,300,412		N PATENT DOCUMENTS		1 - 3	011 21	2004
	<u> </u>	T .	- TOKETO	N 171241 2000		TECH	CENTE	3,1600
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	МО
	AL						 	
	AM				<u> </u>		<u> </u>	
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	t Pages,	Etc.)		
Щи	Hendel, R.C., et al., "Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion," Journal of The American Heart Association, 101(2):118-121, (2000).							
dw	AS	Aoki, M., et al., "Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets," Gene Therapy, 7(5):417-427, (2000).						
de	АТ	Myocardium: Clir	Pecher, P., and Schumacher, B.A., "Angiogenesis is Ischemic Human Myocardium: Clinical Results After 3 Years," The Annals of Thoracic Surgery, 69(5):1414-1419, (2000).					
Щw	AU	Kawasuji, M., et al., "Therapeutic Angiogenesis With Intramyocardial Administration of Basic Fibroblast Growth Factor," The Annals of Thoracic Surgery, 69(4):1155-1161, (2000).						
Sh	AV	Rosengart, T.K., et al., "Six-Month Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA," Annals of Surgery, 230(4):466-472, (1999).						
Mu	AW	Laham, R.J., et al., "Intracoronary and Intravenous Administration of Basic Fibroblast Growth Factor: Myocardial and Tissue Distribution," Drug Metabolism and Disposition, 27(7):821-826, (1999).						
Me	AX	Sellke, F.W., et al., "Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results," The Annals of Thoracic Surgery, 65(6):1540-1544, (1998).						
Mw	AY			nerapy of the Human Hea , 97(7):628-629, (1998)		ournal (of The	>
Mu	AZ	Neointimal Hyper	plasia in a	lective ET _A Receptor Ant a Porcine Coronary Ster tion, 97(25):2551-2556,	it Model	.," Jou		of
EXAMIN	IER	lut hi	7	DATE CONSIDERED 3/1/6+3/1/6				

PTO-144	9 REPR	ODUCED		ATTORNEY DOCKET NO. 3033.1000-008	APPLICAT		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT RECEIVED			CEIVE	
		April 2, 2002		FILING DATE January 16, 2002	GROUP 1653	•	Y 2 4 2002
<u></u>	(Use	several sheets if nece		PATENT DOCUMENTS	1 2000	TECH C	ENTER 1600/2
EXAM	1	JC4.			T	SUB-	FILING DATE
INEX INIC TIAL	,	DOCKSENT NUMBER	DATE	NAME	CLASS	CLASS	IF APPROPRIATE
TIAL	ANT .					REC	EIVED
`	PAT	AII & D				JUN	2 0 2002
			FOREIG	N PATENT DOCUMENTS	T	ECH CEN	IER 1600/2900
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinen	t Pages,	Etc.)	
Mu	AR2	Frimerman, A., et al., "Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model," Journal of The American Heart Association, 99(5):697-703, (1999).					
	AS2	Voisard, R., et al., "High-dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis," Coronary Artery Disease, 8(3/4):189-201, (1997).					
	AT2	Nadir, M., et a III in atherosc (1996).	Nadir, M., et al., "Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine," Coronary Artery Disease, 7(11):851-861, (1996).				
	AU2	Munro, E., et al., "Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis," European Journal of Clinical Investigation, 24(11):766-772, (1994).					
	AV2	Chen, S.J., et al., "Mithramycin Inhibits Myointimal Proliferation After Balloon Injury of the Rat Carotid Artery In Vivo," Circulation, 90(5):2468-2473, (1994).					
	AW2	Shi, Y., et al., "Downregulation of c-myc Expression by Antisense Oligonucleotides Inhibits Proliferation of Human Smooth Muscle Cells," Circulation, 88(3):1190-1195, (1993).					
	AX2	Proliferation by	an Antise acoding Pro	E., "Inhibition of Smoonse Oligodeoxynucleotic liferating Cell Nuclear , (1992).	de Targe	eting the	
M	AY2	Activating Pept:	ide (TRAP-5	he Role of Thrombin and 08) in Initiation of T: , 70(1):158-162, (1995	issue Re		eptor
EXAMIN	NER	List Mi)-		DATE CONSIDERED			

P10-144	9 REPRO	DDUCED		ATTORNEY DOCKET NO. 3033.1000-008	APPLICAT			
	INFOR	MATION DISCLOSURE CI IN AN APPLICATION	TATION	APPLICANT Darrell H. Carney		BF	CEI	VE
,	10se	several sheets if nece	essary)	FILING DATE January 16, 2002	GROUP 1653	MA	Y 2 4	
10	0 1	23 1011	v.s.	PATENT DOCUMENTS		TECHC	ENTER	1600/2
EXAM- INER INI-	N. A.	DOCKTONT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING II APPROP	DATE
TIAL						REC	EIV	ΞD
						JUN	2 0 201)2
			FOREIG	N PATENT DOCUMENTS	, 	ECH CEN	T FR 160	n/2an
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	YES	NG PAK
					<u> </u>			
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinen	t Pages,	Etc.)	,	
the	AZ2	Neovascularizati	ion in Norm	ancement of Incisional al Rats by Thrombin and es," J. Clin. Invest.,	d Synthe	etic Th	rombin).
	AR3	Carney, D.H., e Postclotting Cel Hemostasis, 18(1	llular Effe	e of High-Affinity Throcts of Thrombin," Seminary (1992).	ombin Re	ceptor: Thromb	s in osis a	nd
	AS3	Stiernberg, J., in normal rats h and Regeneration	by the synt	cceleration of full-the hetic thrombin peptide -215, (2000).	ickness , TP508,	wound l ," Wound	nealin d Repa	g ir
	AT3	Glenn, K.C., et Receptors and Mo 1(2):65-73, (198	dulate Thr	hetic Peptides Bind to ombin Mitogenesis," Pep	High-Ai ptide Re	finity esearch	Throm	bin
	AU3	Gene Expression	in Fibrobl	mbin Peptide, TP508, In asts through a Nonproto 1 Research, 247:422-43	eolytic	Activat	ntial tion	
A	AV3	Interaction with	n High-Affi	g Cellular Effects of the nity Thrombin Receptors pp. 351-396, (1992).	Thrombin s," Thro	n Media ombin:	ted by Struct	ure
								
								
								
EXAMIN	VED.)	DATE CONSIDERED				
DVM.IT.		Udit Mu	k,	3/1/04				

PTO-144	9 REPRODUCED		3033.1000-008	APPLICAT		
SU	PPLEMETNAL INFORMATION CITATION IN AN APPL	N DISPLOSERE C,	APPLICANT	120,030		
	CITATION IN AN APPL	ICATION (S)	Charrell H. Carney			
	July 23, 200	······································	ILING-DATE	GROUP		
	(Use several sheets if		July 16, 2002	1653		
		ATENT TIPM	PATENT DOCUMENTS			
exam- Iner Ini- Fial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DA IF APPROPRIA
TAL .					RECE	WED
					JUL 3 ;	2002
				TECH	CENTER	1600/2900
		TODAY.	DI DISTRICTION DOCUMENTS			. 000/2390
		FOREIG	N PATENT DOCUMENTS		SUB-	TRANSLATI
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES
M	AL WO 88/03151	05-MAY-88	PCT			
			,			
	OTHER DOCUMEN	TTS (Including Au	thor, Title, Date, Pert.	inent Pages,	Etc.)	A
ł						
						 .
İ						
j						
					-	
				·		
-		•				
L EXAMIN	PD //		DATE CONCIDEDED			
	ER MIT	As to	DATE CONSIDERED	1///		
	11 1	~// /	, TTI	11/07/		

_ .

	REPRODUCED		OIPE	ATTORNEY DOCKET NO. 3033.1000-008	APPLICAT			
2 nd • 5	CITATIO	AL INFORMATION N IN AN APPLICA tober=28,=2002	DISCLOSURE TION	APPLICANT Darrell H. Carney				
	Oc	tober-28,-2002	2002	FILING DATE	GROUP			
	(Use sever	al sheets if nece	(mary) cer	July 16, 2002	1653			
			U.S.	PATENT DOCUMENTS				
EXAM- INER INI- TIAL	DO	CUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING II APPROP	F
				·				
		,						
			FOREIG	N PATENT DOCUMENTS			<u>.</u>	
\vdash			1			SUB-	TRANSL	ATTON
	DO	CUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	МО
Mr.)	AM WO	02/04008	17 JAN 02	PCT	-	_		
100								
								
<u> </u>								
	0'	THER DOCUMENTS	(Including Au	thor, Title, Date, Perti	nent Pages,	Etc.)		
	Resp Chor	ponses in Ani cioallantoic	imal Models Membranes,	nrombin Peptide, TP5 of Dermal Wound Hea and in Cultured Hum Cells," Gen. Pharmac	ling, in C an Aortic	hick and		
			 					
		-				. <u>.</u>		
				R	CEIVE			
				N	0V 0-8 2002			
				TECH (CENTER 1600/	2900		
		<i></i>			· · · · · · · · · · · · · · · · · · ·			
EXAMINE		(AR)		DATE CONSIDERED 3 ///04				

Ì	PTO-1449 REPRODUCED	_	3033.1000-008	APPLICATION NO. 10/050,611	
I	PHIRD SUPPLEMENTAL INFORMATION IN AN APPL		APPLICANT Darrell H. Carney		
	June 12, 2003 J (Use several sheets if nec	,	-FILING-DATE- January 16, 2002	CONFIRMATION NO.	GROUP 1653

ASK-DE	MACON			
			ATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
Ju	AC	US 2002/0061852 A1	23 MAY 2002	Carney
				RECEIVED
		,		JUN 2 6 2003
				·
				TECH CENTER 1600/2900
		· - - -		

DATE CONSIDERED DATE CONSIDERED		
1 - W/WY 311109	10/1/A/1/2	ach law 2/1/all

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3033.1000-008		LICATION NO. 1050,611	
O 1 P E IN AN APPLICATION	FIRST NAMED INVENTOR Darrell H. Carney		FILING DATE January 16,	2002
JAN 1 2 2004 Use several sheets if necessary)	EXAMINER Not Provided	CONFI 6599	RMATION NO.	GROUP 1653

<u></u>		7		
TRAI	DEMAT	U.S. 1	PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
14)	AD	6,033,436	03/07/2000	Steinke et al.
	:			
-				
-				

EXAMINER	DATE CONSIDERED
10 Signit	311/09